| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem] |
| Indication |
For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria |
| Pharmacology |
Cetirizine, the active metabolite of the piperazine H1-receptor antagonist hydroxyzine, is used to treat chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis. |
| Toxicity |
Somnolence (sleepiness or unusual drowsiness), restlessness, irritability |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine |
| Half Life |
8.3 hours |
| Protein Binding |
Very high (93%) plasma protein binding |
| Clearance |
* 53 mL/min [healthy] |
| External Links |
|